Difference between revisions of "Coltuximab ravtansine (SAR-3419)"
Jump to navigation
Jump to search
m (Jwarner moved page SAR3419 to Coltuximab ravtansine (CoR, SAR3419)) |
m |
||
| Line 3: | Line 3: | ||
=Preliminary studies= | =Preliminary studies= | ||
| + | ==[[Diffuse large B-cell lymphoma]]== | ||
# '''Abstract:''' B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 29: 2011 (suppl; abstr 8017) [http://meetinglibrary.asco.org/content/78324-102 link to original abstract] | # '''Abstract:''' B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 29: 2011 (suppl; abstr 8017) [http://meetinglibrary.asco.org/content/78324-102 link to original abstract] | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category: | + | [[Category:Intravenous chemotherapy]] |
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
| + | [[Category:Antibody medications]] | ||
[[Category:Antibody-drug conjugates]] | [[Category:Antibody-drug conjugates]] | ||
| + | [[Category:Anti-CD19 antibodies]] | ||
| + | |||
| + | [[Category:Diffuse large B-cell lymphoma medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 20:31, 26 November 2014
Mechanism of action
Antibody-drug conjugate
Preliminary studies
Diffuse large B-cell lymphoma
- Abstract: B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 29: 2011 (suppl; abstr 8017) link to original abstract